Gladstone, Lundbeck Collaborate To Study, Identify Neurovascular Therapeutic Candidates

The agreement funds research at the Gladstone Center for Translational Research led by Gladstone investigator Katerina Akassoglou, PhD and establishes the new Lundbeck Center for Neurovascular and Immuno-imaging at the Gladstone Institute of Neurological Disease.

Dr Akassoglou said: “Our research on the role of blood proteins in brain functions has identified new targets for therapeutic intervention in multiple sclerosis and other neurological diseases. Collaborating with the outstanding scientists at Lundbeck, offers great hope for discovering what triggers these diseases and developing novel therapeutic agents.”

Peter Hongaard Andersen, EVP of research at H Lundbeck, said: “Through its basic research into the origins of neurological disease, Gladstone has built an impressive knowledge into potential strategies and targets for treating devastating neurological diseases, such as multiple sclerosis and Alzheimer’s disease. We are looking forward to applying new imaging technologies to help evaluate and translate these discoveries into patient benefits.”

R Sanders Williams, president of Gladstone, said: “Lundbeck is a truly visionary company with a well-focused strategy for building a pipeline to treat neurological disease. We are enthusiastic about the potential of this important collaboration.”

The Gladstone Institutes includes Gladstone Institute of Cardiovascular Disease, the Gladstone Institute of Virology and Immunology, and the Gladstone Institute of Neurological Disease.

Denmark-based H Lundbeck, an international pharmaceutical company, is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington’s, epilepsies, Alzheimer’s and Parkinson’s diseases.